Response to Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
作者信息
Boscoe Audra, McCracken Rebecca, Marathe Punit, Osman Kareem
机构信息
VP, HEOR & Data Science Analytics, Agios Pharmaceuticals, Inc., Cambridge, MA.
Global Scientific Communications & Publications, Agios Pharmaceuticals, Inc., Cambridge, MA.
出版信息
Am J Ther. 2025;32(1):e50-e52. doi: 10.1097/MJT.0000000000001786. Epub 2024 Aug 21.
Abstract
摘要
相似文献
1
Response to Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.对米他匹伐的反应：一种用于治疗丙酮酸激酶缺乏症成人溶血性贫血的喹诺酮磺酰胺。
Am J Ther. 2025;32(1):e50-e52. doi: 10.1097/MJT.0000000000001786. Epub 2024 Aug 21.
2
Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.米他匹伐：一种用于治疗丙酮酸激酶缺乏症成人溶血性贫血的喹诺酮磺酰胺类药物。
Am J Ther. 2023;30(5):e433-e438. doi: 10.1097/MJT.0000000000001663.
3
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.评估米他膦酸酯治疗丙酮酸激酶缺乏症成人溶血性贫血。
Expert Rev Hematol. 2022 Oct;15(10):875-885. doi: 10.1080/17474086.2022.2125865. Epub 2022 Sep 22.
4
Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.米他匹伐：丙酮酸激酶缺乏症成人溶血性贫血的一种新型治疗方法。
Curr Med Chem. 2024;31(6):683-687. doi: 10.2174/0929867330666230430002709.
5
How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency.我们如何治疗丙酮酸激酶缺乏所致的溶血性贫血。
Hematol Rep. 2024 Aug 31;16(3):559-567. doi: 10.3390/hematolrep16030054.
6
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.米替培南侧重于安慰剂用于治疗丙酮酸激酶缺乏症。
N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634.
7
Mitapivat for Acquired Pyruvate Kinase Deficiency.米塔匹瓦特用于治疗获得性丙酮酸激酶缺乏症。
Pediatr Blood Cancer. 2025 Feb;72(2):e31440. doi: 10.1002/pbc.31440. Epub 2024 Nov 13.
8
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.米拉帕维特治疗接受常规输血的丙酮酸激酶缺乏症成年患者（ACTIVATE-T）：一项多中心、开放标签、单臂、3 期临床试验。
Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18.
9
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.米他匹伐，一种新型丙酮酸激酶激活剂，用于治疗遗传性溶血性贫血。
Ther Adv Hematol. 2021 Dec 21;12:20406207211066070. doi: 10.1177/20406207211066070. eCollection 2021.
10
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.米他培坦：成人丙酮酸激酶缺乏症的治疗药物。
Drugs. 2023 Nov;83(17):1613-1620. doi: 10.1007/s40265-023-01961-x. Epub 2023 Nov 22.
本文引用的文献
1
Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.长期接受米他匹瓦特治疗的丙酮酸激酶缺乏成年患者的骨矿物质密度
Haematologica. 2024 Mar 1;109(3):963-967. doi: 10.3324/haematol.2023.282884.
2
Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.米他匹伐：一种用于治疗丙酮酸激酶缺乏症成人溶血性贫血的喹诺酮磺酰胺类药物。
Am J Ther. 2023;30(5):e433-e438. doi: 10.1097/MJT.0000000000001663.
3
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.米拉帕维特治疗接受常规输血的丙酮酸激酶缺乏症成年患者（ACTIVATE-T）：一项多中心、开放标签、单臂、3 期临床试验。
Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18.
4
Mitapivat versus Placebo for Pyruvate Kinase Deficiency.米替培南侧重于安慰剂用于治疗丙酮酸激酶缺乏症。
N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634.
5
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.米他培坦治疗丙酮酸激酶缺乏症的安全性和疗效。
N Engl J Med. 2019 Sep 5;381(10):933-944. doi: 10.1056/NEJMoa1902678.
Zotero 插件